Related Experiment Video

Updated: Sep 26, 2025

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.7K

Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID-19 vaccination: A case report

Shakiba Hassanzadeh1, Somayeh Sadeghi2, Ahmad Mirdamadi3

  • 1Division of Pathology Nickan Research Institute Isfahan Iran.

Clinical Case Reports
|April 20, 2022
PubMed

Insights

A case study reports myocarditis in a 32-year-old female after the first AstraZeneca COVID-19 vaccine dose. While a direct link is unconfirmed, this highlights potential risks of adenovirus vector vaccines.

Area of Science:

  • Cardiology
  • Vaccinology
  • Public Health

Background:

  • Global administration of COVID-19 vaccines has led to monitoring of adverse events.
  • Myocarditis, an inflammation of the heart muscle, has been reported post-vaccination, predominantly after mRNA vaccines.
  • Emerging reports suggest potential myocarditis risk following adenovirus vector vaccines.

Observation:

  • A 32-year-old female presented with exertional tachycardia and dyspnea.
  • Symptoms began approximately three days after receiving the first dose of the AstraZeneca vaccine.
  • Myocarditis was diagnosed via echocardiography three months post-vaccination.

Findings:

  • This case presents a potential association between adenovirus vector COVID-19 vaccination and myocarditis.
  • The patient experienced symptoms consistent with myocarditis following the AstraZeneca vaccine.
  • A direct causal link between the vaccine and myocarditis remains unconfirmed in this instance.

Implications:

  • Increased awareness is needed regarding the possibility of myocarditis after adenovirus vector COVID-19 vaccines.
  • Further research may be warranted to investigate the incidence and mechanisms of myocarditis post-AstraZeneca vaccination.
  • This case contributes to the ongoing pharmacovigilance of COVID-19 vaccines.
Keywords:
AstraZeneca‐associated myocarditisCOVID‐19 vaccination‐associated myocarditismRNA COVID‐19 vaccinesmyocarditisviral vector vaccines

More Related Videos

Intracranial Injection of Adeno-associated Viral Vectors08:47

Intracranial Injection of Adeno-associated Viral Vectors

Published on: November 17, 2010

47.9K
Ultrasound-guided Transthoracic Intramyocardial Injection in Mice08:22

Ultrasound-guided Transthoracic Intramyocardial Injection in Mice

Published on: August 5, 2014

15.2K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
25
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
35
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
51
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
46
Pericarditis I: Introduction01:22

Pericarditis I: Introduction

Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
28
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
39